Selective elimination of BRCA1-deficient cells by inhibitors of poly(ADP-ribose) polymerase (PARP) is a prime example of the concept of synthetic lethality in cancer therapy. This interaction is counteracted by the restoration of BRCA1-independent homologous recombination through loss of factors such as 53BP1, RIF1, and REV7/MAD2L2, which inhibit end resection of DNA double-strand breaks (DSBs). To identify additional factors involved in this process, we performed CRISPR/SpCas9-based loss-of-function screens and selected for factors that confer PARP inhibitor (PARPi) resistance in BRCA1-deficient cells. Loss of members of the CTC1-STN1-TEN1 (CST) complex were found to cause PARPi resistance in BRCA1-deficient cells in vitro and in vivo. We show that CTC1 depletion results in the restoration of end resection and that the CST complex may act downstream of 53BP1/RIF1. These data suggest that, in addition to its role in protecting telomeres, the CST complex also contributes to protecting DSBs from end resection.
INTRODUCTION
The synthetic lethal interaction between BRCA1 deficiency and poly(ADP-ribose) polymerase (PARP) inhibition is a well-established therapeutic paradigm with encouraging response rates in the clinic (Lord and Ashworth, 2017) . This has resulted in the recent regulatory approval of three PARP inhibitors (PARPis) for the treatment of serous ovarian cancers and one PARPi, olaparib, for the treatment of BRCA-mutated, HER2-negative breast cancers. Moreover, the BRCA-PARP paradigm might be extended beyond breast and ovarian cancer because recent clinical studies indicate that a subset of prostate cancers harbor a homologous recombination (HR) defect and, hence, might benefit from olaparib treatment (Mateo et al., 2015; Pritchard et al., 2016) .
Despite this success, long-lasting clinical response rates in patients with advanced disease are limited by the development of resistance, the mechanisms of which have not been fully elucidated. A major class of resistance mechanisms centers on reexpression of functional BRCA1 or BRCA2 protein, either through promoter demethylation, genetic reversion, or gene fusions (Patch et al., 2015; Swisher et al., 2008; Ter Brugge et al., 2016) . However, our previous work also identified the existence of additional BRCA1-independent resistance mechanisms in the K14cre; Brca1 F/F ;p53 F/F (KB1P) genetically engineered mouse model of hereditary breast cancer (Liu et al., 2007) . In this model, re-expression of functional BRCA1 is excluded because of the large, engineered, intragenic Brca1 deletion, which spans multiple exons. Despite the absence of functional BRCA1 restoration, KB1P tumors acquired resistance to PARPi treatment. In addition to activation of the P-glycoprotein drug efflux transporter (Rottenberg et al., 2008) , the BRCA1-independent resistance mechanisms in KB1P tumors predominantly involved the partial restoration of HR activity through re-wiring of the DNA damage response (DDR); for example, by loss of 53BP1 (Bouwman et al., 2010; Bunting et al., 2010; Jaspers et al., 2013) . et al., 2013; Zimmermann et al., 2013) and REV7/MAD2L2 (Boersma et al., 2015; Xu et al., 2015) . However, the currently known resistance factors cannot explain all PARPi-resistant cases, suggesting that additional proteins functioning in this pathway remain to be identified. Moreover, although the loss of resection antagonists partially restores end resection of DNA double-strand breaks (DSBs), none of these factors have direct functions in DNA metabolism, raising the question of how DNA metabolism at DSBs might be altered to stimulate end resection.
The function of the 53BP1 pathway is not exclusive to canonical DSB repair, but it also acts on telomeres (Panier and Boulton, 2014) . Because telomere ends resemble DSBs located at chromosomal termini, cells have evolved several mechanisms to protect telomeres from DSB end processing and chromosome endto-end fusions (Sfeir and de Lange, 2012) . Mammalian telomeres consist of TTTAGG repeats ending with a single-strand G-rich overhang. The single-stranded DNA (ssDNA) overhang is crucial in telomere maintenance because it is required for the formation of the T-loop structure (Makarov et al., 1997; McElligott and Wellinger, 1997) . Notably, excessive resection of telomere ends is inhibited by the action of the shelterin complex and by the 53BP1 pathway (Lazzerini-Denchi and Sfeir, 2016; Sfeir and de Lange, 2012) .
Besides the mechanisms that have evolved to protect telomeric overhangs from excessive processing, it has recently been shown that the RPA-like CTC1-STN1-TEN1 (CST) complex is able to localize to telomeric ssDNA and mediate a fill-in reaction executed by polymerase-alpha (POLA) to buffer resection activity (Feng et al., 2017; Miyake et al., 2009; Wu et al., 2012) . Notably, it was demonstrated that the binding of the CST complex to ssDNA is not particularly sequence-specific, although a partial preference for G-rich regions has been described (Hom and Wuttke, 2017; Miyake et al., 2009) . Additionally, CST components do not localize exclusively to telomeres (Miyake et al., 2009 ). This might argue that the CST complex also has non-telomeric functions.
In this study, three independent forward genetic CRISPR/ SpCas9-based loss-of-function screening approaches were employed to identify factors that induce PARPi resistance in BRCA1-deficient cells. Together, these screens identified that defects in Ctc1, or its CST complex members Stn1 or Ten1, suppress the synthetic lethal interaction between BRCA1 and PARP inhibition. Inactivation of CTC1 is sufficient to drive PARPi resistance in vivo. Depletion of CTC1 increased end resection activity and subsequently restored RAD51 focus formation upon ionizing radiation (IR)-induced DNA damage, providing a mechanistic basis for these observations. Moreover, the CST complex facilitates canonical non-homologous end joining (c-NHEJ)-driven repair.
Together, these data demonstrate that the CST complex plays a more global role in DNA repair beyond the protection of telomeres.
RESULTS

Forward Genetic CRISPR/SpCas9 Screens Identify Selective Enrichment for Loss of CTC1 during PARPi Treatment in BRCA1-Deficient Cells
To identify factors that modulate the synthetic lethal interaction between BRCA1 and PARP, we carried out three independent forward genetic loss-of-function CRISPR/SpCas9 screens (Figure 1) . All screens were analyzed by harvesting cells before and after PARPi treatment, after which single guide RNA (sgRNA) sequences were amplified from genomic DNA by PCR and analyzed by next-generation sequencing. The screening data were processed by the model-based analysis of genome-wide CRISPR-Cas9 knockout (MAGeCK) or the drugZ algorithm (Li et al., 2014; Wang et al., 2017) , and the results were sorted on positive selected gene ranks to allow comparison across screens. Additional experimental details are provided in the Supplemental Experimental Procedures.
The first PARPi resistance screen was performed in SpCas9-expressing KB1P-G3 mouse mammary tumor cells (Jaspers et al., 2013 ) using a custom-made lentiviral sgRNA library targeting 1,752 DDR-related genes (Table S1 ) cloned into the doxycycline-inducible pLenti-sgRNA-tetR-T2A-PuroR vector (Prahallad et al., 2015) . The screen was performed at 1003 coverage, and cells were selected with two different PARPis, olaparib and AZD2461 (Oplustil O'Connor et al., 2016) , at the approximate inhibitory concentration 90 (IC90) for 14 days ( Figure 1A ). Although sgRNAs targeting Tp53bp1 were deliberately removed from the library to avoid the possibility that this potent PARPi resistance factor might obscure the effects of other genes, its upstream regulatory factor Rnf8 scored among the top genes ( Figure 1B) .
The second PARPi resistance screen was performed in SpCas9-expressing Brca1
À/À mouse embryonic stem cells (mESCs) infected with a genome-wide lentiviral sgRNA library targeting 19,150 genes (Koike-Yusa et al., 2014) . The screen was performed at 753 coverage in two independent transductions, and cells were selected with olaparib at a concentration of 15 nM for 10 days. As expected, Tp53bp1 and Rnf8 scored among the top genes and ranked #1 and #15, respectively ( Figure 1C) . A third PARPi resistance screen was performed in BRCA1 2288delT mutant SUM149PT human breast cancer cells (Elstrodt et al., 2006) . SUM149PT cells expressing doxycycline-inducible SpCas9 were lentivirally infected with a genome-wide sgRNA library targeting 18,010 genes (Tzelepis et al., 2016) . This screen was performed at 1,0003 coverage, and cells were selected in the presence of doxycycline plus 100 nM talazoparib for 2 weeks. The screen was dominated by sgRNAs targeting PARP1, the drug target of talazoparib. Although PARP1 loss is expected to be lethal in BRCA1-deficient cells, the selection for PARP1 loss in SUM149PT cells might be attributed to residual BRCA1 activity, which might enable cell survival in the absence of PARP1 (Pettitt et al., 2017; Wang et al., 2016) . Moreover, TP53BP1 scored among the top enriched genes and ranked #7 ( Figure 1D ). The results from these three independent screens were collated to identify consistent outliers. The top 20 genes were selected from the DDR-focused library screen in KB1P-G3 cells. Because the genome-wide libraries contain about 10-fold more genes than the DDR-focused library, the top 200 genes were selected from the mESC and SUM149PT screens, and these were plotted in a Venn diagram ( Figure 1E ). Notably, Ctc1 was the only gene that consistently scored in all three screens (ranked #10, #39, and #39 in the KB1P-G3, mESC, and SUM149PT screens, respectively). Moreover, Stn1 (also known as Obfc1) scored in two of three screens. These results caught our attention because both CTC1 and STN1 are members of the CST complex. Although the CST complex has known functions in telomere metabolism, these PARPi resistance screens might point toward non-telomeric functions of the CST complex. Because Ctc1 was a top hit in all three independent screens in both mouse and human cells, we prioritized this gene for further validation.
Depletion of CTC1 Suppresses the Synthetic Lethal
Interaction between BRCA1 Deficiency and PARP Inhibition To validate the effect of CTC1 on PARPi sensitivity in BRCA1-deficient cells, we transfected KB1P-G3 cells with pX330 vectors containing three sgRNAs targeting a putative oligonucleotidebinding (OB) fold domain of Ctc1 (Figure 2A ). The polyclonal targeted populations were efficiently modified for the target site ( Figures 2B-2D) , as shown by TIDE (tracking of insertions or deletions [indels] by decomposition) analysis (Brinkman et al., 2014) . These populations were subsequently treated with olaparib (75 nM) or AZD2461 (250 nM), the same concentrations as used for the screen. As expected, parental KB1P-G3 cells or KB1P-G3 cells targeted by a non-targeting sgRNA (sgNT) showed high sensitivity to PARPi treatment. In contrast, Ctc1-targeted cells showed resistance to treatment, indicating that depletion of CTC1 suppresses the synthetic lethal interaction between BRCA1 deficiency and PARP inhibition ( Figures 2E and F) . This could not be attributed to an effect on cell proliferation because we observed no difference in the doubling time upon depletion of CTC1 ( Figure 2G ).
We next investigated whether Ctc1-mutated cells would be specifically selected out from a mixed population by prolonged PARPi treatment. A competition assay was performed in which 
;Trp53
À/À mouse embryonic stem cells (mESCs) were screened with a genome-wide library in two independent transductions at 753 coverage. After 10 days of culture in the presence of olaparib (15 nM), treated populations were compared with the untreated population using MAGeCK software. Gene based p values were log-transformed and plotted based on the positive rank (enrichment). Each dot represents a unique gene. (D) A derivative of the BRCA1 mutant SUM149PT human triple-negative breast tumor cell line carrying a doxycycline-inducible SpCas9 expression construct was lentivirally infected with a genome-wide guide RNA library at more than 1,0003 coverage. Cells were cultured in the presence of doxycycline plus 100 nM talazoparib for 2 weeks. The sgRNA abundance in treated populations was compared with the starting population using drugZ. Gene-based Z scores were logtransformed and plotted based on the positive z-rank (enrichment). Each dot represents an individual gene.
(E) The top 20 genes in the KB1P-G3 screen and the top 200 genes in the mESC and SUM149PT screens were selected and plotted in a Venn diagram to identify consistent outliers. (B-D) KB1P-G3 cells were transfected with pX330puro vectors containing the indicated sgRNAs, and the target region was PCR-amplified to verify allele modification using TIDE software.
(E) The indicated Ctc1-mutated KB1P-G3 cell lines were plated for clonogenic growth upon olaparib (75 nM) or AZD2461 (250 nM) treatment. Three independent experiments were performed, and each condition was plated in triplicate. One representative well per condition is shown for each independent experiment. (F) Quantification of crystal violet staining in (E). Data were plotted relative to the growth of untreated sgNT cells and are presented as mean ± SD (n = 3 independent experiments). Significance was calculated by two-way ANOVA with Dunnett's multiple comparisons test (****adjusted p = 0.0001).
(G) Relative cell proliferation was determined by IncuCyte Zoom Live -Cell Analysis System measurements. Each data point represents the average of three independent experiments, and in each experiment, six replicate wells were measured and averaged. Data represent mean ± SD (n = 3). Doubling times (exponential growth equation) were calculated using GraphPad software, and significance was calculated by one-way ANOVA with Dunnett's multiple comparisons test.
(H and I) SpCas9-expressing KB1P-G3 cells were transduced with doxycycline-inducible pLenti-sgRNA-tetR-T2A-PuroR vectors containing the indicated sgRNAs. Polyclonal populations were plated for clonogenic growth with or without AZD2461 (250 nM) (H). Cells were passaged every 10 days for a total of three times. At the endpoint, wells were fixed and stained with crystal violet, and allele distributions were determined from each condition using TIDE software (I).
(J) KB1P-G3 cells were transfected with pX330puro vectors containing sgRNAs targeting Stn1 and Ten1 and cultured in the presence or absence of 75 nM olaparib as in (E). Data were analyzed as in (F) and reflect at least two independent experiments. the evolution of polyclonal populations was monitored by the TIDE algorithm to quantify changes in allele distributions. sgRNAs were cloned in the pLenti-sgRNA-tetR-T2A-Puro vector and introduced in SpCas9-expressing KB1P-G3 cells by lentiviral transduction. The population was mutagenized by doxycycline-induced expression of the sgRNA for 5 days, after which cells were plated without doxycycline for clonogenic growth. After 10 days of culture in the presence or absence of AZD2461, the cells were harvested and re-plated at equal amounts every 10 days for an additional two rounds, resulting in a total treatment duration of 30 days. Although non-transduced cells or cells transduced with a non-targeting sgRNA were effectively killed by this prolonged treatment, Ctc1-targeted cells survived (Figure 2H) . This coincided with an enrichment of Ctc1 frameshift mutations compared with untreated populations, which were kept in culture for the same duration ( Figure 2I ). To study whether this effect is CTC1-specific or a feature of the CST complex, we genetically inactivated the other two CST complex members Stn1 and Ten1, and treated these cells with olaparib under the same conditions as used for Ctc1. CRISPR/ SpCas9-mediated disruption of Stn1 or Ten1 also induced PARPi resistance, recapitulating the effect of Ctc1 ( Figure 2J ). This is consistent with the identification of STN1 in the PARPi resistance screens ( Figure 1E ) and shows that PARPi sensitivity is modulated by all CST complex members rather than CTC1 alone.
These data were corroborated in Brca1
which CRISPR/SpCas9-assisted inactivation of Ctc1 increased survival upon olaparib treatment, which was accompanied by a selection for frameshifting alleles (Figures S1A and S1B). Furthermore, we targeted the CST complex members in R26
CreERT2
;Brca1 SCo/D mESCs, which harbor a selectable conditional Brca1
Sco allele that can be inactivated by CreERT2 through the addition of 4-hydroxytamoxifen (4-OHT) (Bouwman et al., 2010) . Although 4-OHT-induced inactivation of BRCA1 caused lethality in untransduced R26
;Brca1 SCo/D mESCs, clonal outgrowth was observed for cells depleted of CTC1, STN1, or TEN1 ( Figure 3A ). Complete switching of the conditional Brca1 Sco allele in the surviving population was confirmed by PCR, ruling out that clonal outgrowth was due to a non-recombined Brca1
Sco allele ( Figure 3B ). Finally, depletion of CTC1 in SUM149PT cells enhanced cell survival in the presence of talazoparib, as did depletion of 53BP1 ( Figure 3C ), confirming that this effect was not restricted to mouse cells. In summary, we confirmed that the CST complex promotes PARPi-induced cell lethality in BRCA1-deficient cells. We therefore looked at the role of the CST complex in preventing global DNA damage, focusing on CTC1.
CTC1 Antagonizes End Resection at Non-Telomeric DSBs
During the repair of DSBs, a critical decision is made between initiating repair via NHEJ or via HR, which both require distinct end processing. This decision is tightly balanced by end protection factors, such as 53BP1 or RIF1, which antagonize resection to direct repair via NHEJ, and BRCA1, which promotes end resection to direct repair via HR (Chapman et al., 2013 CreERT2 ;Brca1 SCo/D mESCs using pLentiCRISPRv2 vectors. Following transduction and selection, the Brca1-Sco allele was recombined by activation of CreERT2 via addition of 4-OHT, after which cells were plated out for clonogenic growth. Cells were fixed and stained with crystal violet. (B) Brca1 alleles from surviving populations were PCR-amplified using specific primers to detect Brca1 Sco (Sco) and recombined Brca1 DSco (DelSco) alleles.
(C) BRCA1-mutant SUM149PT cells were transfected with the EditR CRISPR system, and the indicated CRISPR RNA (crRNA) and then continuously cultured in the presence of 50 nM talazoparib over a 14-day period, at which point cell viability was estimated by use of CellTiter-GLo reagent. Median effects from three independent experiments are shown. Error bars represent SEM. *p = 0.0415 and 0.0201, respectively; **p = 0.0013 and 0.0011, respectively; ****p = < 0.0001; unpaired two-tailed Student's t test.
Panier and Boulton, 2014). It was previously shown that the end resection defect in BRCA1-deficient cells can be rescued via loss of 53BP1, and this also rescued cell lethality induced by BRCA1 loss (Bouwman et al., 2010; Bunting et al., 2012) . Hence, the finding that loss of the CST complex ( Figure 3A ) rescued BRCA1 lethality points toward a potential inhibitory role in DSB end resection. Moreover, depletion of CTC1 did not induce PARPi resistance in BRCA2-deficient cells (Figures S2A and S2B) , which is in line with a possible role of the CST complex upstream of BRCA2. DSB end resection produces ssDNA overhangs, which are protected from nucleolytic degradation and the formation of secondary structures by the coating of RPA. Therefore, we visualized RPA loading in response to a-particle-induced DNA damage by immunofluorescence as a readout for end resection (Stap et al., 2008) . In line with previous studies (Tká c et al., 2016; Xu et al., 2015) , KB1P-G3 tumor cells showed a clear resection defect that was partially restored in Ctc1-mutated KB1P-G3 cells but not in sgNT-transfected control cells (Figures 4A and 4B) .
We next investigated whether CTC1 loss affects the recruitment of DDR factors to sites of irradiation-induced DNA damage. CRISPR/SpCas9-targeted KB1P-G3 cells were either left untreated or treated with 10 Gy of IR, which potently induced yH2AX foci (Figures 4C and 4D; Figures S3A and S3B) . Although depletion of 53BP1 in KB1P-G3 cells abolished the formation of IR-induced 53BP1 and RIF1 foci, these effects were not observed in CTC1-depleted cells (Figures 4E and 4F and S3C and S3D) . Despite the capacity to form 53BP1 and RIF1 foci, KB1P-G3 cells that were depleted of CTC1 restored IR-induced RAD51 focus formation, whereas sgNT-transfected control cells were deficient for this activity ( Figures 4G and S3E ). Similar conclusions were obtained when DNA damage was induced by treatment with 500 nM olaparib for 24 hr (Figures S3A and S3F-S3M). As expected, PARPi treatment resulted in more heterogeneous DNA damage induction compared with IR because PARP inhibition primarily exerts its cytotoxic effects during replication. We then tested whether CTC1 loss resulted in productive HR events in conditional BRCA1-deficient R26
CreERT2 ;Brca1 SCo/D ; Pim1 DR-GFP/wt mESC cells carrying a stably integrated DR-GFP reporter (Bouwman et al., 2013) . These cells were transfected to transiently express mCherry and I-SceI, and the percentage of mCherry/GFP double-positive cells was quantified by fluorescence-activated cell sorting (FACS) 24 hr later. Switching of the conditional Brca1 SCo allele impaired HR activity, which was partially rescued upon depletion of the CST complex ( Figures  S3N and S3O ). Together, these data support a role for CTC1 as a resection antagonist acting on non-telomeric DSBs and as a mediator of the HR defect in BRCA1-deficient cells.
CTC1 Facilitates c-NHEJ-Mediated Repair at Telomeric and Non-Telomeric DSBs
It was previously shown that 53BP1, RIF1, and REV7/MAD2L2 antagonize resection and promote c-NHEJ (Boersma et al., 2015; Bouwman et al., 2010; Bunting et al., 2010; Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Díaz et al., 2013; Xu et al., 2015; Zimmermann et al., 2013) . However, this is not a universal phenotype for resection antagonists because it is not shared by HELB (Tká c et al., 2016) . We therefore sought to determine whether CTC1 affects NHEJ activity. First, we used Terf2
À/À mouse embryonic fibroblasts (MEFs) that express a temperature-sensitive TRF2 Ile468Ala mutant (TRF2ts) (Konishi and de Lange, 2008) . TRF2ts is functional and maintains intact TRF2-protected telomeres at 32 C, but it dissociates from telomeres at 37 C-39 C, inducing a DDR response and end-to-end chromosome fusions (Konishi and de Lange, 2008) . It was previously demonstrated that these fusions are driven by c-NHEJ and can be rescued by depletion of RNF8, DNA ligase IV, or REV7/MAD2L2 (Boersma et al., 2015; Celli and de Lange, 2005; Peuscher and Jacobs, 2011; Smogorzewska et al., 2002) .
We depleted CTC1 in TRF2ts MEFs grown under permissive conditions ( Figure 5A ), which did not affect cell cycle distribution ( Figures S4A and S4B ). Cells were then grown at the non-permissive temperature (39 C) for 24 h to uncap telomeres and induce a DDR response prior to harvesting metaphase spreads for telomere fluorescence in situ hybridization (FISH). Although chromosome fusions were readily observed in control cells upon temperature-induced TRF2 inactivation, this was significantly reduced in Ctc1-mutated cells (Figures 5B and 5C; . In line with this finding and with NHEJ being inhibited by long ssDNA overhangs, it was previously shown that depletion of CTC1 increased ssG overhang length (Chen et al., 2012; Gu et al., 2012) .
We next assessed whether CTC1 depletion in mouse CH12 B cells affects the ability to undergo class switch recombination (CSR) as a measure for non-telomeric c-NHEJ capacity (Muramatsu et al., 2000) . CH12 cells were transfected with Ctc1-targeting CRISPR/SpCas9 constructs and subcloned to obtain Ctc1-mutated CH12 cell clones. Notably, only 2 of 96 tested clones showed heterozygous Ctc1 allele disruption, and no homozygous knockouts were obtained ( Figures S4F and S4G ), raising the possibility that complete loss of CTC1 is lethal in CH12 cells. Wild-type and heterozygous Ctc1 knockout clones were subsequently stimulated with CD40Ab, interleukin-4 (IL-4), and transforming growth factor b-1 (TGF-b-1, CD40Ab, IL-4, and TGFb-1 [CIT]) to induce CSR from immunoglobulin M (IgM) to IgA, which was monitored by flow cytometry. Interestingly, heterozygous knockout of Ctc1 significantly diminished CSR in both clones ( Figures 5D and 5E ). We therefore conclude that CTC1 facilitates DSB repair via c-NHEJ at both telomeric and non-telomeric regions.
Depletion of CTC1 Mediates PARPi Resistance in the KB1P Mouse Model
Last, we explored the in vivo effects of CTC1 on the treatment response of BRCA1-deficient tumors to PARP inhibition. We analyzed whether Ctc1 mRNA expression levels were altered in our previously generated collection of BRCA1-and p53-deficient KB1P and KB1PM mouse mammary tumors with acquired resistance to PARP inhibition (Jaspers et al., 2013) . In total, this collection comprises 60 treatment-naive tumors and 85 matched PARPi-resistant tumors derived from 23 unique donors. To examine the expression levels of Ctc1 in treatment-naive and PARPi-resistant tumors, we produced RNA sequencing (RNAseq) data for all tumors (E.G., unpublished data) and obtained the normalized expression values using edgeR (Robinson et al., 2010) . We observed that the expression of Ctc1 is significantly downregulated in PARPi-resistant tumors compared with naive tumors (p = 6.34 3 10 À4 ) ( Figure 6A ). Moreover, in tumors for which copy number variation by sequencing (CNVseq) data were available, CTC1 mRNA downregulation correlated with CNV loss (Figures S5A and S5D ). Although a similar correlation was observed for STN1 and TEN1, these factors were not significantly downregulated in resistant tumors ( Figures S5B, S5C , S5E, and S5F). Finally, we used mammary tumor organoid technology (Duarte et al., 2018) to perform an in vivo intervention study with the PARPi olaparib in mice carrying tumors derived from isogenic KB1P organoids with or without disruption of Ctc1. For this purpose, KB1P4 organoids, derived from a KB1P mammary tumor, were cultured ex vivo and co-transduced with lentiviruses produced from pCMV-SpCas9 and pLenti-sgCtc1-tetR-T2A-Puro vectors. Control organoids were generated by co-transduction with pCMV-SpCas9 and pLenti-sgNT-tetR-T2A-Puro lentivirus encoding a non-targeting sgRNA ( Figure 6B ). The transduced KB1P4 tumor organoids were orthotopically transplanted in mice that were left untreated or treated daily with the PARPi olaparib for 56 consecutive days when tumors reached a size of 50-100 mm 3 . As expected, the Ctc1 target site was efficiently disrupted in tumors derived from KB1P4 organoids transduced with pCMV-SpCas9 and pLenti-sgCtc1-tetR-T2A-Puro ( Figures  6C and 6D ). Although KB1P4 control tumors only relapsed after treatment was stopped, CTC1-depleted tumors relapsed during treatment, resulting in accelerated mammary tumor-related death (median latencies: 39 days for sgCtc1_2 and 42 days for sgCtc1_3 cohorts compared with 73 days for control animals; log rank test, p = 0.0019 and p = 0.0086, respectively; Figure 6E ). These data confirmed that depletion of CTC1 confers PARPi resistance in BRCA1-deficient tumors in vivo.
DISCUSSION
In this study, we show that loss of the CST complex members CTC1, STN1, and TEN1 induces PARPi resistance in tumors with irreversible loss of function of BRCA1. Our data highlight the CST complex as a pathway for tumor cells to escape the synthetic lethal effects of PARPi by restoring HR independently of BRCA1. In particular, we demonstrate that the underlying mechanism is a restoration of end resection of DSBs. Together, our findings demonstrate that the CST complex contributes to the regulation of DNA end stability not only at telomeres but also at non-telomeric DSBs.
We and others have recently shown that the 53BP1-RIF1-REV7/MAD2L2 pathway is crucial for blocking end resection of DSBs (Boersma et al., 2015; Bouwman et al., 2010; Bunting et al., 2010; Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Díaz et al., 2013; Xu et al., 2015; Zimmermann et al., 2013) . However, it has remained elusive how DNA end stability is regulated by 53BP1-RIF1-REV7/MAD2L2 because none of these factors have been shown to contain direct DNA binding capacity and do not contain DNA processing activities. Our finding that the CST complex functions as a resection antagonist at Chromosomes were stained with DAPI and a telomere-specific FISH probe (green). (C) Metaphases were detected and imaged automatically by Metafer. At least two independent experiments were performed, in each independent experiment, more than 2,000 chromosomes were counted manually. Genotypes were blinded during counting. Data are plotted as mean ± SEM. Significance was determined by unpaired two-tailed Student's t test (*p % 0.05; **p % 0.01). DSBs sheds light on this puzzle. The CST complex is an RPA-like complex that can directly bind ssDNA via multiple OB folds (Miyake et al., 2009 ). In collaboration with the laboratory of Dan Durocher, we recently identified another RPA-like complex, the Shieldin (SHLD) complex, which is composed of SHLD1 (C20ORF196), SHLD2 (FAM35A), SHLD3 (FLJ26957/CTC-534A2.2), and REV7/MAD2L2, as a downstream effector of 53BP1 in DSB repair (unpublished data). Hence, in addition to RPA and the SHLD complex, the CST complex is another trimeric complex that contains direct DNA binding capacity and affects DSB end stability. How these three complexes are recruited to DSBs in time and space remains to be elucidated. Possibly, RPA, SHLD, and CST compete for ssDNA at resected DSBs or collapsed forks to either promote or antagonize HR. Not mutually exclusive with this model, it is conceivable that these complexes might contain specialized functions dependent on the ssDNA substrate since the CST complex has been reported to preferentially bind to and promote melting of G-rich regions and G4-quadruplexes (Bhattacharjee et al., 2017; Lue et al., 2013) . Future work is also required to elucidate whether these complexes form the final step in the regulation of DSB end stability (for instance, through steric hindrance) or whether additional downstream factors are involved. Intriguingly, the CST complex has been described to buffer resection at telomeres via POLAdependent fill-in DNA synthesis, which is required to prevent excessive telomere erosion (Lazzerini-Denchi and Sfeir, 2016) . Our finding that the CST complex antagonizes resection at non-telomeric DSBs raises the question of whether this is dependent on POLA activity. Resection can possibly be antagonized not only by shielding the ends of DSBs from end-processing activities but also by directly counteracting ongoing resection via fill-in DNA synthesis. This buffering activity might fine-tune the length of ssDNA around the DSB, which is vulnerable for nucleolytic degradation, and it might provide a rescue mechanism in case HR cannot be completed.
The identification of the CST complex as a mediator of PARPi response in BRCA1-deficient tumors might also have clinical implications because loss-of-function mutations in the CST-encoding genes are predicted to cause clinical PARPi resistance. Moreover, we expect that these alterations provide therapeutic vulnerabilities because we recently found that depletion of the 53BP1-dependent DNA repair pathway enhances sensitivity to IR (M.B., unpublished data).
EXPERIMENTAL PROCEDURES Cell Culture and Gene Editing
The KB1P-G3 cell line was previously established from a K14cre;Brca1 Cell Reports 23, 2107-2118, May 15, 2018 2115
Genomic DNA Isolation, PCR Amplification, and TIDE Analysis Allele modification frequencies were quantified from genomic DNA isolated from tumor and cell line samples using Gentra Puregene (QIAGEN) according to the manufacturer's protocol. Target loci were amplified by PCR and submitted for Sanger sequencing to confirm target modification using the TIDE algorithm (Brinkman et al., 2014) . Parental cells were used as a reference sequence. PCR primer sequences are provided in Table S3 . Further details are provided in the Supplemental Experimental Procedures.
CRISPR Library Screens
Screening details are provided in the Supplemental Experimental Procedures.
Alpha Track Assay
Experiments were performed as described previously (Xu et al., 2015) with minor modifications. Details are provided in the Supplemental Experimental Procedures.
Focus Formation Experiments RAD51 immunofluorescence in CRISPR/SpCas9-transfected KB1P-G3 cells was performed as described previously with minor modifications (Xu et al., 2015) . Details are provided in the Supplemental Experimental Procedures.
DR-GFP
The DR-GFP was performed as described previously (Bouwman et al., 2013) . Genes were targeted using the pLentiCRISPRv2 system containing the indicated sgRNAs.
Assessment of Telomere NHEJ Trf2
;TRF2ts (TRF2ts) MEFs were described before (Peuscher and Jacobs, 2011) , and metaphase chromosome analysis was done as described before (Boersma et al., 2015) . Details are provided in the Supplemental Experimental Procedures.
CSR Assay
Immunoglobulin CSR was performed as described previously (Xu et al., 2015) . Details are provided in the Supplemental Experimental Procedures.
Generation of RNA-Seq Data
To determine the effects of Ctc1, Ten1, and Stn1 on PARPi treatment in vivo, we used our RNA-seq dataset generated from a cohort of PARPi-naive and -resistant KB1P and KB1PM tumors (Jaspers et al., 2013; E.G., unpublished data) . Further details are provided in the Supplemental Experimental Procedures.
Generation of CNV Sequencing Data
Genomic DNA was isolated from a subset of matched naive-and resistant KB1P-derived fresh-frozen tumor material using standard phenol:chloroform extraction (Jaspers et al., 2013; E.G., unpublished data). Further details are provided in the Supplemental Experimental Procedures.
In Vivo Studies
All animal experiments were approved by the Animal Ethics Committee of the Netherlands Cancer Institute (Amsterdam, the Netherlands) and performed in accordance with the Dutch Act on Animal Experimentation (November 2014). Tumor organoids were allografted in 6-to 9-week-old female mice as described previously (Duarte et al., 2018) with minor modifications. Further details are provided in the Supplemental Experimental Procedures.
Quantification and Statistical Analysis
Statistical differences were calculated in GraphPad Prism using Student's t tests. Statistical significance in Figure 2F was calculated by two-way ANOVA and post hoc Dunnett's correction for multiple comparisons and in Figure 2G by one-way ANOVA and post hoc Dunnett's correction for multiple comparisons. Statistical differences in Figures 4D-4G and Figures S3F-S3M were calculated by Kruskal-Wallis non-parametric test and post hoc Dunnett's correction for multiple comparisons. Statistical differences in Figure 6E were calculated by log rank Mantel-Cox test. Significance is as follows: p > 0.05, not significant (n.s.); *p % 0.05; **p % 0.01; ***p % 0.001; ****p % 0.0001 unless otherwise stated in the figure legends. Original data files used to prepare the figures in this manuscript have been deposited in Mendeley Data and are available at https://doi.org/10.17632/6wyzgw8z8k.1.
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by S.R. (sven.rottenberg@vetsuisse.unibe.ch).
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw data of RNA-seq and CNV sequencing reported in this paper is European Nucleotide Archive (ENA): PRJEB25803.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, five figures, and three tables and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.04.046.
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Zimmermann, M., Lottersberger, F., Buonomo, S.B., Sfeir, A., and de Lange, T. for 7 days before wells were fixed and stained with crystal violet. The experiment was performed in duplicate. Ctc1 was mutated using the pLenti-sgRNA-tetR-T2A-PuroR vector containing the indicated gRNAs. Allele distributions were determined from the starting population and the surviving population after treatment.
(B) Quantification of A. The number of colonies was determined using GelCount software. Data represent the relative number of colonies compared to the parental untreated mES cells. Data represent mean ± SD. P-values were determined by unpaired two-tailed students t-test (P = 0.0074 and P = 0.0017, respectively). (A-B) Parental, sgNT or Ctc1-mutated KB2P-3.4 SpCas9 expressing cells were plated at 2,000 cells per 6-well for clonogenic growth in the presence or absence of olaparib (50 nM) for 10 days. Then, cells were harvested and re-plated at 2,000 cells per 6-well under the same treatment for 10 days, and this was repeated one more time (total treatment duration 30 days). Ctc1 was mutated using the pLenti-sgRNA-tetR-T2A-PuroR vector containing the indicated gRNAs. Cells were selected with puromycin (3 μg/mL) and gRNA expression was induced with doxycycline (3 μg/mL) for 5 days. Allele distributions were determined from the starting, untreated and olaparib-treated populations and the percentage indel is shown and plotted in B. DR-GFP-hygro/wt mES-cells using pLentiCRISPRv2 vectors containing indicated sgRNAs. Cells were treated with 4-OHT to inactivate the Brca1
Sco allele and subsequently transfected with mCherry/I-SceI constructs. HR activity was determined by flow cytometry and was calculated as the percentage of GFP+ cells in the mCherry+ population relative to BRCA1 proficient parental cells. The experiment was performed three times and the data are plotted as mean with SEM. Statistics was performed by unpaired one-tailed students t-test (* = p-value <0.05; ** = p-value <0.01). Bottom boxplots indicate correlation between copy number changes and expression changes. Adjusted P-value were obtained by one-way anova and Tukey multiple pairwise-comparison. * Adj. P-value < 0.1, ** Adj. P-value < 0.05, *** Adj. P-value <0.01.
Supplemental Experimental Procedures
Cell culture KB1P and KB2P mouse mammary tumor cell lines were cultured in DMEM/F-12 medium (Life Technologies) in the presence of 10% FCS, penicillin/streptomycin (Gibco), 5μg/mL insulin (Sigma), 5ng/mL epidermal growth factor (Life Technologies) and 5ng/mL cholera toxin (Gentaur) under low oxygen conditions (3% O 2 , 5% CO 2 at 37 o C). SUM149PT cells were cultured in Ham's F12 medium (Gibco) supplemented with 5% FCS, 5 µg/ml insulin, 1 μg/mL hydrocortisone (Sigma-Aldrich, St. Louis, MI, USA (Bouwman et al., 2010; Bouwman et al., 2013) were cultured on gelatin-coated plates in 60% buffalo red liver (BRL) cell conditioned medium supplied with 10% fetal calf serum, 0.1 mM β-mercaptoethanol (Merck) and 10 3 U/ml ESGRO LIF (Millipore) under normal oxygen conditions (21% O 2 , 5% CO 2 , 37°C). Trf2 -/-p53 -/-TRF2ts MEFs were grown in DMEM with 100U penicillin, 0.1 mg/ml streptomycin, 2mML-glutamine and 10%FBS. TRF2ts MEFs were maintained at the permissive temperature of 32 o C and only grown at 39 o C to induce telomere uncapping through inactivation of TRF2 (Peuscher and Jacobs, 2011) .CH12F3 cell lines were cultured in RPMI supplemented with 5 % NCTC-109 medium, 10% FCS, 100 U/ml penicillin, 100 ng/ml streptomycin and 2 mM L-glutamine at 37°C with 5% CO 2 under ambient oxygen conditions. KB1P4 3D tumor organoid cells were seeded in Basement Membrane Extract Type 2 (BME, Trevigen) on 24-well suspension plates (Greiner Bio-One) and cultured in AdDMEM/F12 supplemented with 1 M HEPES (Sigma), GlutaMAX (Invitrogen), penicillin/streptomycin (Gibco), B27 (Gibco), 125 µM N-acetyl-Lcysteine (Sigma), 50 ng/mL murine epidermal growth factor (Invitrogen).
Transfection-based genome editing
Transfection in KB1P-G3 cells was performed using TransIT-LT1 (Mirus) reagents following manufacturer's recommendations. In brief, 150,000 cells were plated in 6-well format 1 day before transfection with 1 µg DNA. The medium was refreshed 24 hours after transfection and transfected cells were selected with puromycin for three days. CRISPR/SpCas9 targeted SUM149PT cells were generated with editR crRNA (Dharmacon, Lafayette, CO, USA).
Lentiviral transduction-based genome editing
Cell lines targeted with the pGSC_Cas9_Neo and pLenti-sgRNA-tetR-T2A-Puro system were generated by lentiviral transduction. Lentivirus was produced in HEK293FT cells as described previously (Follenzi et al., 2000) and mouse KB1P-G3 or Brca1 -/-;p53 -/-mES cells were infected overnight using polybrene (8 µg/mL). The medium was refreshed after 12 hours and transduced cells were selected with puromycin (3 µg/mL) and blasticidin (500 µg/mL) for five consecutive days. KB1P4 tumor organoids were transduced using spinoculation as described previously (Duarte et al., 2018; Koo et al., 2011) . Expression of the sgRNA was induced by incubation with 3 μg/ml doxycycline (Sigma) for at least five days.
Plasmids
pGSC_Cas9_Neo and pLenti-sgRNA-tetR-T2A-Puro were described previously (Prahallad et al., 2015) . Genomewide mouse lentiviral CRISPR sgRNA library was a gift from Kosuke Yusa (Addgene #50947). Human Improved Genome-wide Knockout CRISPR Library v1 was a gift from Kosuke Yusa (Addgene #67989). pX330-U6-Chimeric_BB-CBh-SpCas9 was a gift from Feng Zhang (Addgene plasmid # 42230). pLentiCRISPRv2 was a gift from Feng Zhang (Addgene plasmid # 52961). The MCherry/I-SceI plasmid has been described previously (Bouwman et al., 2013) .
Generation of CRISPR/SpCas9 plasmids
Unless otherwise stated, KB1P-G3 experiments were performed using a modified version of the pX330 backbone (Cong et al., 2013) in which a puromycin resistance ORF was cloned under the hPGK promoter (Harmsen et al., 2018) . sgRNA sequences were cloned in the pX330puro backbone using custom DNA oligos (IDT) which were melted, annealed and subsequently ligated with quick-ligase (NEB) into BbsI-digested backbone. A similar procedure was used for cloning into the pLenti-sgRNA-tetR-T2A-Puro vector, but using BfuAI-digested backbone. All constructs were sequence verified by Sanger sequencing. sgRNA sequences are provided in Table S2 .
Genomic DNA isolation, PCR amplification and TIDE analysis
Target loci were amplified by PCR using the following conditions: (1) 98 °C, 30 s, (2) 30 cycles of 98 °C for 10 s, 61 °C for 20 s and 72 °C for 30 s, (3) 72 °C, 5 min. Reaction mix consisted of 0.75 μl DMSO, 5 μl GC Phusion Buffer 5X, 0.5 μl 2 mM dNTPs, 0.125 μl 100 μM Fwd oligo, 0.125 μl 100 μM Rev oligo, 0.25 μl Phusion polymerase in 25 μl total volume. Amplified products were diluted 50X in dH 2 O and 2 μl of diluted product was submitted for Sanger sequencing.
CRISPR library screens
The first PARPi resistance screen was performed in the KB1P-G3 tumor cell line, which was previously established from a KB1P tumor (Jaspers et al., 2013) . This cell line is BRCA1-and p53-deficient through large intragenic deletions and shows sensitivity to PARPi treatment in the nanomolar range. The DDR sgRNA library was generated based on the gene list from Thanos Halazonetis (University of Geneva) described before (Costantino et al., 2014; Xu et al., 2015) and the NCBI search (terms: "DNA repair", "DNA damage response", "DNA replication", "telomereassociated genes") . See Table S1 for the full library details. This search resulted in a DDR-related gene list comprising a total of 1,752 genes (Table S1 ). Tp53bp1 was specifically removed from this list in anticipation that loss of 53BP1 might dominate the screen results and thereby obscure the effects of other genes. sgRNAs targeting the 1,752 DDR-related genes were synthesized (MYcroarray) and cloned into the pLenti-sgRNA-tetR-T2A-PuroR vector, which allows for doxycycline inducible expression of the sgRNA (Prahallad et al., 2015) . KB1P-G3-SpCas9 expressing cells were generated by transduction with the pGSC_SpCas9_Neo vector and transduced cells were selected by 500 µg/mL G418. The pLenti-sgRNA-tetR-T2A-Puro-DDR library was introduced at 100x coverage. Next, doxycycline was added to the medium for 5 days to mutagenize the population. Cells were subsequently plated in a clonogenic growth format in the presence of the PARP inhibitors olaparib or AZD2461 (Oplustil O'Connor et al., 2016) at the approximate IC90 concentration for 14 days. Cells were harvested before and after PARPi treatment for genomic DNA isolation. Subsequently, sgRNA sequences were amplified from genomic DNA by two rounds of PCR amplification as described previously (Duarte et al., 2018) and sequenced with the HiSeq 2500, using the following barcodes: GTAGCC, TACAAG, CTCTAC, GCGGAC, TTTCAC, GGCCAC. Sequencing reads were aligned to the reference sequences using edgeR software (Robinson et al., 2010) . The screening data were processed by the MAGeCK algorithm (Li et al., 2014) , and results were sorted on MAGeCK-based positive selected gene ranks to allow comparison across screens.
The second PARPi resistance screen was performed in BRCA1-and p53-deficient, SpCas9-expressing mouse embryonic stem (mES) cells infected with a genome-wide lentiviral sgRNA library targeting 19,150 genes (KoikeYusa et al., 2014) . The screen was performed at 75x coverage in two independent transductions (MOI 0.5) and cells were first selected with puromycin and subsequently treated with olaparib at a concentration of 15 nM for 10 days. Surviving populations were harvested and processed as described previously (Koike-Yusa et al., 2014) , using the following barcodes CGTGAT, ACATCG, GCCTAA, TGGTCA, CACTGT, ATTGGC, GATCTG, TCAAGT, CTGATC, AAGCTA, GTAGCC, TACAAG, TTGACT, GGAACT. The screening data were processed similar to the screen in KB1P-G3 cells.
A third PARPi resistance screen was performed in the SUM149PT human breast cancer cell line. This cell line harbors the BRCA1 2288delT mutation and LOH (Elstrodt et al., 2006) . A derivative of SUM149PT with an integrated tetracycline-inducible SpCas9 was lentivirally infected with a genome-wide sgRNA library designed to target 18,010 genes (Tzelepis et al., 2016) , using a multiplicity of infection of 0.3 and infecting >1000 cells per sgRNA. After puromycin selection (3 µg/ml) to remove non-tranduced cells, a sample was removed (time or t=0); remaining cells were cultured in the presence or absence of doxycycline plus 100 nM talazoparib, a concentration which normally results in complete inhibition of the cell population. No cells survived in the absence of doxycycline. After two weeks of selection, genomic DNA from the remaining cells in the doxycycline-treated sample was recovered. The sgRNA sequences from this genomic DNA were PCR amplified using barcoded and tailed primers and deep sequenced as previously described (Koike-Yusa et al., 2014) to identify sgRNAs in the talazoparib-resistant population. Read counts were normalized for coverage by converting to parts per ten million (pptm) reads and fold change between starting and resistant population was calculated for each guide. Fold change values were log-and Ztransformed and plotted based on z-rank (Wang et al., 2017) .
Clonogenic survival assay
Ctc1, Stn1 and Ten1 were targeted in R26
CreERT2
;Brca1
SCo/Δ mouse embryonic stem (mES) cells using pLentiCRISPRv2 vectors, Cre-mediated inactivation of the endogenous mouse Brca1
SCo allele was achieved by overnight incubation of cells with 0.5 μmol/L 4-OHT (Sigma) (Bouwman et al., 2010) . Four days after switching, cells were seeded in triplicate at 10,000 cells per well in 6-well plates for clonogenic survival assay. For experiments with R26 CreERT2/wt ;Brca1
SCo/Δ p53-null cells, cells were plated without treatment or in the presence of olaparib 2.5 nM. Cells were stained with 0.1% crystal violet one week later, and scanned with the Gelcount (Oxford Optronix). Automated quantification of colony counts was performed using the Gelcount colony counter software.
Clonogenic survival assay with PARPi (olaparib) were performed as described previously with minor modifications (Xu et al., 2015) . CRISPR/SpCas9 transfected KB1P-G3 cells were seeded in triplicate at 5 x 10 3 cells per well into 6-well plates on day 0, and then olaparib or AZD2461 was added at the indicated concentrations. On day 6, the untreated group was fixed, the other groups were fixed on day 9 and stained with 0.1% crystal violet. Plates were scanned with the Gelcount (Oxford Optronix). Quantifications were performed by solubilizing crystal violet using 10% acetic acid and the absorbance at 562nm was measured using the Tecan plate reader. The experiment was performed three times.
SUM149PT-SpCas9 cells were transfected with CTC1 targeting crRNA and tracrRNA using the EditR system (Life Technologies), plated into 48 well plates and then treated with 50 nM talazoparib. Medium was replaced with fresh drug-containing medium as indicated. Images were taken to measure viability of cells in each well every 12 hours using the IncuCyte system. After two weeks, final viability was assessed using CellTiter Glo (Promega).
Competition assays
Competition assays were performed in KB1P-G3 SpCas9 expressing cells, transduced with pLenti-sgRNA-tetR-T2A-Puro vectors containing the indicated sgRNAs. Cells were selected with puromycin (3 µg/mL) for three days and allowed to recover from selection. A sample was harvested for gDNA isolation at t = 0, and 5,000 cells were plated in 6-well plates in triplicate per condition, with or without AZD2461 (250 nM). After 10 days of treatment, cells were harvested, counted and re-plated at 5,000 cells per 6-well two times (total treatment time of 30 days). On the last time point, each condition was plated as technical duplicate. At the end point, one technical duplicate well was fixed and stained with crystal violet and the other was used to isolate gDNA. Allele distributions were determined from gDNA samples by PCR followed by Sanger sequencing and TIDE analysis, as described above. Competition assays in KB2P-3.4 cells were performed similarly, except 2,000 cells were seeded per 6-well and cells were treated with olaparib (50 nM).
Growth curves
Growth curves were generated for CRISPR/SpCas9 transfected KB1P-G3 cells by seeding 1,000 cells per well in 96-well plates, seeding 6 technical replicates per experiment and the well confluency was recorded every 4 hours for 120 hours using an IncuCyte Zoom Live -Cell Analysis System (Essen Bioscience). The images were analyzed using IncuCyte Zoom software. Data were normalized to the confluency at 20h after seeding.
Alpha track assay
Experiments were performed as described previously (Xu et al., 2015) with small modifications. CRISPR/SpCas9 transfected KB1P-G3 cells were seeded on coverslips overnight, washed with PBS and covered with a mylar foil, allowing α-particle irradiation from above, through mylar. Irradiation was done using a 241 Am point-source by moving the source over the coverslip for 30s per area, cells were incubated for 1 hour at 37 °C and washed with icecold PBS. Subsequently, cells were extracted with cold CSK buffer (10 mM HEPES-KOH, pH 7.9, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 0.5% (v/v) Triton X-100) and cold CSS buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1% (v/v) Tween20, 0.5% (w/v) sodium deoxycholate) for 5 min each before fixation in
